If you have documented semaglutide failure, your provider can use this as leverage for insurance approval of tirzepatide coverage
Your provider should document why the switch is necessary, whether due to inadequate response, side effects, or clinical preference
Employer Implications As oral nonpeptide GLP1s and combination therapies approach market entry, plan sponsors should anticipate expanded utilization, increased clinical complexity and heightened pressure on costcontainment strategies
That was such a great conversation with Ashley
Still, many people get sent to endocrinologists or special clinics to get regular and detailed care if the focus is on treating obesity
6-month: $1,626 ($271/mo)